

Supplementary information, Table S2 Comparisons of clinical manifestations presenting before or at admission in nifedipine-treated group with those in general SFTS group or non-nifedipine group.

	Nifedipine-treated group (n=83)	General SFTS group (n=249)	Non-nifedipine group (n=48)	<i>P</i> ^a	<i>P</i> ^b
Age, years	64.5 ± 8.7	64.9 ± 10.4	62.6 ± 8.9	0.803	0.227
Sex, female	57 (68.7)	171 (68.7)	35 (72.9)	1.000	0.609
Delay from symptom onset to admission, days	5 (4-6)	5 (4-6)	5 (4-7)	0.805	0.684
Fever	83 (100)	249 (100)	48 (100)	1.000	1.000
Feeble	81 (97.6)	241 (96.8)	46 (95.8)	1.000	0.624
Dizzy	7 (8.4)	29 (11.6)	3 (6.3)	0.542	0.745
Headache	6 (7.2)	19 (7.6)	2 (4.2)	0.904	0.710
Chills	2 (2.4)	14 (5.6)	0	0.237	0.532
Myalgias	53 (63.9)	154 (61.8)	29 (60.4)	0.744	0.695
Arthralgia	0	2 (0.8)	0	1.000	1.000
Lymphadenopathy	42 (50.6)	114 (45.8)	25 (52.1)	0.446	0.870
Cough	16 (19.3)	33 (13.3)	5 (10.4)	0.180	0.183
Sputum	9 (10.8)	14 (5.6)	2 (4.2)	0.105	0.184
Anorexia	72 (86.7)	205 (82.3)	38 (79.2)	0.310	0.255
Nausea	46 (55.4)	126 (50.6)	22 (45.8)	0.447	0.290
Vomit	12 (14.5)	40 (16.4)	7 (14.6)	0.727	0.984
Abdominal pain	3 (3.6)	9 (3.6)	1 (2.1)	1.000	1.000

Diarrhea	12 (14.5)	49 (19.7)	13 (27.1)	0.287	0.076
Ecchymosis at venipuncture site	8 (9.6)	25 (10)	3 (6.3)	0.916	0.745
Gingival bleeding	0	1 (0.4)	0	1.000	-
Melena	0	3 (1.2)	0	0.576	-
Petechia	0	0	1 (2.1)	-	1.000
Hematemesis	1 (1.2)	1 (0.4)	0	0.438	1.000
Convulsion	2 (2.4)	4 (1.6)	3 (6.3)	0.642	0.139
Dysphoria	2 (2.4)	5 (2.0)	0	1.000	1.000
Confusion	2 (2.4)	9 (3.6)	3 (6.3)	0.737	0.355
Lethargy	1 (1.2)	3 (1.2)	1 (2.1)	1.000	1.000
Coma	0	4 (1.6)	1 (2.1)	0.576	1.000

^aindicates difference between nifedipine-treated group and general SFTS group;

^bindicates difference between nifedipine-treated group and non-nifedipine group.